Navigation Links
Jennerex and Green Cross Announce Publication of Positive Clinical Data of JX-594 in Combination With Sorafenib in Advanced Liver Cancer
Date:4/20/2011

SAN FRANCISCO and SEOUL, South Korea, April 20, 2011 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Green Cross Corporation, a leading company in the development, manufacturing, and commercialization of viral vaccines and other biological products, today reported positive clinical data from a Phase 2 trial evaluating JX-594 for liver cancer which was conducted in South Korea.  The data were reported in the journal Molecular Therapy.

Patients enrolled in a Phase 2 clinical trial for hepatocellular carcinoma (HCC) received three intratumoral administrations of JX-594.  A subset of three patients subsequently received sorafenib, the current standard of care for HCC and the only approved systemic therapy for this indication to date.  All three of these patients exhibited rapid and marked tumor necrosis as quantitated by serial dynamic MRI imaging; all patients had both Choi (necrotic) and modified Response Evaluation Criteria in Solid Tumor (mRECIST) type responses.  The responses were rapid—as early as 2.5 weeks after sorafenib initiation—and occurred in both JX-594-injected and non-injected tumors.  Notably, similar responses were not seen in HCC patients treated with sorafenib alone at the same institutions (zero of 15 patients). The treatment regimen was well tolerated in each of the patients, and sorafenib toxicities were consistent with the documented historical profile. The JX-594-sorafenib combination regimen is currently being further investigated in another Phase 2 trial.

"Given the strength of the clinical and preclinical data we have observed from our JX-594 trials in liver cancer, we are planning further clinical trials of JX-594 as a single agent and in combination with VEGFR inhibitors.  TRAVERSE, our planned randomized Phase 2b clinical tr
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
2. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
3. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
4. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
5. Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer
6. Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Research
7. Jennerex, Inc. Receives EMEA Orphan Drug Designation for JX-594 for the Treatment of Hepatocellular Carcinoma
8. Jennerex Announces Presentations at Upcoming Conferences
9. Jennerex Appoints Gregory W. Schafer as Chief Financial Officer
10. Jennerex Appoints Lara Longpre to Chief Operating Officer
11. Jennerex Names Dr. Mark P. Backer as Senior Vice President of Technical Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( ... of directors of Advaxis, Inc. ("Advaxis" or the "Company") ... has breached its fiduciary duties to shareholders. ... an investing website reporting that Advaxis had misrepresented the ...
(Date:1/23/2015)...  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced that the number ... lead compound, LB‑100, is being conducted, has been expanded from ... , M.D., the founder and President of Lixte, said that, ... single site. Accrual of patients, however, was slower than projected. ...
(Date:1/23/2015)... , Jan. 23, 2015 Gem Pharmaceuticals announced today ... been enrolled into the Company,s Phase 2 clinical trial. ... of Gem,s lead compound, GPX-150 (an investigational medication), in ... metastatic disease. Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
(Date:1/22/2015)... January 22, 2015 Blue Cross and Blue ... who exemplify what it means to “Live Fearless.” ... people to share their stories about how they or someone ... inspired others by living in the moment. By telling these ...
(Date:1/22/2015)... 22, 2015 Thousand of GranuFlo lawsuits ... recalled its GranuFlo and NaturaLyte dialysis concentrates continue to ... U.S. District Court, District of Massachusetts, Bernstein Liebhard LLP ... Court has remanded a case filed by the state ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 A ... Sports Medicine flagship journal Medicine & Science in ... before exercise may help reduce gastrointestinal (GI) problems ... , Participants in the double-blind, placebo-controlled study ...
(Date:1/22/2015)... DC (PRWEB) January 22, 2015 Payday ... in vulnerable communities and cause financial distress to the ... by analysts at Howard University’s Center on Race and ... dollars in economic activity, payday loans at the same ...
(Date:1/22/2015)... a new blog post explaining the importance of keeping a first ... an auto insurance policy . , Clients who driver safer ... vehicle insurance policies. The safety a vehicle offers from its driver ... this, drivers should always carry a first aid kit in their ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2
... Elsevier, a world-leading publisher of medical information products and ... Medical Press (PUMP) it has donated over 5,000 books ... The initiative is supported by the Development Centre for ... book donation is in line with the spirit of ...
... Rainbow Kitchen celebrates its 25th year of service to the ... period of economic hardship means that the help the organization ... , The 25th anniversary will be marked with a ... Scott Lammie - UPMC Health Plan,s Chief Financial Officer and ...
... ... Electronic Payment Exchange (EPX), a leading merchant acquirer ... data field encryption best practices provides welcome leadership to merchants, technology ... of data breach. EPX is the first payment processor to offer ...
... ... direct-to-consumer provider of premium dietary supplements, announces the release of their Mediterranean Diet ... ... a leading direct-to-consumer provider of premium dietary supplements, announces the release of their ...
... ... therapy affect integration into society,• Marriage is predicted by height, physical functioning, cognitive outcomes ... Philadelphia ... effects of cancer treatment on physical health, and results of a new study suggest ...
... LAKE CITY, Oct. 7 Utah residents will have access ... tomorrow. The Utah Drug Card is a free discount prescription ... to 75% on prescription drugs at retail pharmacies. All Utah ... printing a card on the program,s website www.utahdrugcard.com ...
Cached Medicine News:Health News:Elsevier's Health Sciences Division and Peking University Medical Press cooperate on book donation 2Health News:Rainbow Kitchen Celebrates 25th Anniversary in Pittsburgh 2Health News:Electronic Payment Exchange Welcomes New Visa Best Practices for Data Field Encryption 2Health News:Electronic Payment Exchange Welcomes New Visa Best Practices for Data Field Encryption 3Health News:Purity Products Releases Their Brand New Mediterranean Diet Resveratrol Formula 2Health News:Survivors of Childhood Cancer Less Likely to Marry 2Health News:Survivors of Childhood Cancer Less Likely to Marry 3Health News:Survivors of Childhood Cancer Less Likely to Marry 4
Ophthalmic Nd Yag Laser with excellent quality optics for clear image and good laser delivery. Compact and light-weight for portability....
The first daily disposable lens for presbyopia....
... of corneal layers: endothelium, descemet's ... layers. Accurate analysis of corneal ... nerve fibres, basal & superficial ... and pathology: optical pachymetry, post-surgery ...
Ahmed Glaucoma Valve (small size)....
Medicine Products: